Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00582985 · ClinicalTrials.gov registry record · Phase 1
Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer
A Phase 1 study, sponsored by Tracon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT00582985 is a Phase 1 study that has completed, run by Tracon Pharmaceuticals. The registered enrollment target is 51 participants.
The verdict
NCT00582985, a Phase 1 study, has completed, sponsored by Tracon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
This study is being performed to evaluate the safety and tolerability of the TRC105 monoclonal antibody.
Interventions
- DRUG TRC105 chimeric anti-CD105 antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2007-12 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00582985
The ClinicalTrials.gov registry entry for NCT00582985 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tracon Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TRC105 chimeric anti-CD105 antibody is the first listed.
NCT00582985 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00582985 about?
NCT00582985 is a clinical study titled "Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer". This study is being performed to evaluate the safety and tolerability of the TRC105 monoclonal antibody.
What is the current status of trial NCT00582985?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2007-12. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00582985?
The interventions under investigation include: TRC105 chimeric anti-CD105 antibody (DRUG).
Who is sponsoring clinical trial NCT00582985?
This trial is sponsored by Tracon Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.